Our 2017 Cancer Immunotherapy 2.0 report featured in Drug Development & Delivery

By |2018-09-12T21:30:40+00:00November 21, 2017|Cancer, Drug Development, Haberman Associates, Immunology|

 

Drug Development and Delivery published an article based on our 2017 report on Cancer Immunotherapy 2.0 in its November/December 2017 issue.

To see the article, please go to http://www.drug-dev.com/Main/Back-Issues/CANCER-IMMUNOTHERAPY-Building-on-Initial-Successes-1402.aspx

To order our report, Cancer Immunotherapy: Building on Initial Successes to Improve Clinical Outcomes, please see the CHI Insight Pharma Reports website.

As the producers of this blog, and as consultants to the biotechnology and pharmaceutical industry, Haberman Associates would like to hear from you. If you are in a biotech or pharmaceutical company, and would like a 15-20-minute, no-obligation telephone discussion of issues raised by this or other blog articles, or of other issues that are important to your company, please contact us by phone or e-mail. We also welcome your comments on this or any other article on this blog.

 

Leave A Comment